Pristiq patents expiration

PRISTIQ's oppositions filed in EPO
PRISTIQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(1 year, 6 months ago)

US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(3 years from now)

Pristiq is owned by Pf Prism Cv.

Pristiq contains Desvenlafaxine Succinate.

Pristiq has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Pristiq are:

  • US6673838

Pristiq was authorised for market use on 29 February, 2008.

Pristiq is available in tablet, extended release;oral dosage forms.

Pristiq can be used as for the approved uses and conditions of use, including depression; maintenance treatment of major depressive disorder (mdd).

The generics of Pristiq are possible to be released after 05 July, 2027.

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Market Authorisation Date: 29 February, 2008

Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)


How can I launch a generic of PRISTIQ before it's drug patent expiration?
More Information on Dosage

PRISTIQ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic